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INTRODUCTION
α1-Antitrypsin (AAT) is a serine pro-
tease inhibitor and treatment with AAT
prolongs islet allograft survival in mice
(1). Moreover, AAT gene therapy modu-
lates cellular immunity and efficiently
prevents the development of type 1 dia-
betes in nonobese diabetic mice (2–4).
AAT significantly reduces cytokine- and
streptozotocin (STZ)-induced β-cell apo-
ptosis by abolishing caspase-3 activity
(5). AAT treatment also induces immune
tolerance (6) and dampens inflammation,
resulting in the expansion of the func-
tional mass of β-cells in nonobese dia-
betic (NOD) mice (7), whereas this effect
is not observed in a nonautoimmune
mouse strain (8).
The association of AAT with diabetes
was initially investigated by analyzing
the meconium of infants delivered via
cesarean section to diabetic mothers (9).
The highest AAT concentration was ob-
served in the third trimester of the dia-
betic pregnancy. However, the increased
concentration of AAT in the sera of preg-
nant diabetic women did not correlate
with the glycemic control value (9). A
study reported that the urine sample of
diabetic patients had markedly increased
AAT concentrations (10). The presence of
increased AAT levels in patients with di-
abetes mellitus was suggested by the re-
duction of inhibitory capacity on serum
proteinases (11–14); however, the precise
molecular mechanism underlying the
loss of AAT-mediated inhibitory func-
tions is not clear.
The hereditary disorder of AAT defi-
ciency is caused by mutations in the α1-
antitrypsin (SERPINA1) gene (15,16), and
the most common form of AAT defi-
ciency occurs because of the Z mutation
(17,18), resulting in aberrant folding and
accumulation of the protein in the endo-
plasmic reticulum (ER). This step leads to
ER stress and contributes significantly to
liver disease. AAT is also synthesized by
monocytes, neutrophils and epithelial
cells (19,20). The unfolded AAT protein is
activated in quiescent monocytes and
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contributes to an inflammatory pheno-
type, with Z mutation (ZZ) monocytes
exhibiting enhanced cytokine production
and activation of the nuclear factor (NF)-
κB pathway when compared with normal
M variant (MM) monocytes (19). These
findings changed the previous paradigm
of lung inflammation in AAT deficiency
due to defects in AAT- mediated inhibi-
tion of neutrophil proteinase.
AAT-mediated suppression of formyl-
met-leu-phe (fMLP)-stimulated and non-
stimulated neutrophil adhesion to fi-
bronectin, as well as the inhibition of
lipopolysaccharide (LPS)-induced inter-
leukin (IL)-8 release and delayed neu-
trophil apoptosis, is independent of the
inhibition of neutrophil proteinase activ-
ity (21). The effect of AAT on TNFα-
 induced self-expression is inhibited by the
oxidation and modification of AAT, which
abolishes the serine protease-inhibitor ac-
tivity of AAT (22). These data further sup-
port the idea that the antiinflammatory
function of AAT is independent of its in-
hibitory effect on elastase. In general, the
patterns of gene expression regulated by
native and oxidized AAT are similar, with
neither of them stimulating proinflamma-
tory genes or cytokine expression (23).
In the present study, we generated a
recombinant form of AAT as a chimeric
protein fused to Fc and successfully pro-
duced much recombinant AAT-Fc pro-
tein from stable clones of Chinese ham-
ster ovary (CHO) cells. We evaluated the
antiinflammatory properties of the puri-
fied AAT-Fc protein in vitro and in vivo.
Our results demonstrate that the biologi-
cal properties of AAT-Fc are very similar
to those of plasma-derived AAT and that
the antiinflammatory activity of AAT-Fc
is more potent than that of plasma-
 derived AAT.
MATERIALS AND METHODS
Recombinant AAT-Fc Protein
Expression
Human pCAGGs-IgG1/AAT plasmids
were cotransfected with the pSV-
 dihydrolfolate reductase (DHFR) vector
(ATCC, Manassas, VA, USA) into the
DHFR-deficient CHO cell line (DG44). 
Stable clones were selected in medium
containing G418 (500 μ/mL) and subse-
quently subjected to methotrexate selec-
tion for gene amplification as previously
described (24). The CHO stable clones that
secrete soluble recombinant AAT-Fc were
grown in serum-free medium (CHO-
SSFMII; Life Technologies, Carlsbad, CA,
USA), as previously described (24).
Purification of AAT-Fc
The single cell clone selected was cul-
tured in a 2-liter flask. The culture medium
was first filtered through membranes with
a pore size of 0.2 μm to remove debris.
The flow-through result was then purified
with protein A–conjugated beads that had
been equilibrated with phosphate-
buffered saline (PBS) containing 0.5 mol/L
NaCl. The filtered cell culture medium
was passed through a column containing
the protein A resin, and 1-mL fractions of
purified protein were collected. Glycine
(pH 2.7) was used as the elution buffer,
and the fractions were neutralized imme-
diately with 100 μL of 1 mol/L Tris base.
Western Blotting
For the detection of recombinant
AAT-Fc protein, aliquots of the purified
protein fractions were analyzed by
sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE) on 10%
acrylamide gels. The resolved proteins
were transferred to a nitrocellulose mem-
brane and Western blotting analysis was
performed using rabbit anti-human AAT
(YbdY, Seoul Korea) and horse radish
peroxidase–conjugated goat anti-human
IgG Fc antibodies (Sigma-Aldrich, St.
Louis, MO, USA). The protein-antibody
complexes were detected by using Supex
(Neuronex, Seoul, Korea) and an LAS-
4000 imaging device (Fujifilm, Japan).
Inhibitory Effect of AAT-Fc on the
Enzymatic Activity of Elastase
Elastase (20 ng; Athens Research and
Technology, Athens, GA, USA) and IL-32γ
(20 ng; YbdY) were incubated in 20 μL
PBS (pH 7.4) at room temperature for
10 min in the presence or absence of
AAT-Fc. After completion of the reaction,
the samples were subjected to SDS-PAGE
and Western blotting analysis. A human
IL-32–specific polyclonal antibody
(YbdY) was used for detecting cleaved
IL-32γ. A similar experiment was per-
formed, and the reactions were used to
assess the effect of AAT-Fc on the elas-
tase-mediated cleavage of IL-32γ by
using an IL-32γ–specific enzyme-linked
immunosorbent assay (ELISA), instead
of Western blotting analysis.
Cytokine Assays
To examine the effect of AAT-Fc on
TNFα- or LPS-induced cytokine produc-
tion, peripheral blood mononuclear cells
(PBMCs) were preincubated with
plasma-derived AAT or AAT-Fc for 1 h
and then simulated with fresh medium
(0.2 mL) containing human TNFα (YbdY)
or LPS (Sigma-Aldrich). Raw 264.7 cells
were seeded in 96-well plates at a density
of 1 × 105 cells per well 1 d before stimu-
lation. The plated cells were preincubated
for 1 h with plasma-derived AAT or AAT-
Fc and then stimulated with LPS, human
IL-32, human IL-33 or mouse IL-33
overnight. The cell culture supernatant of
human PBMCs and mouse Raw 264.7
cells was harvested on the next day for
the cytokine assay. Human IL-6 and
mouse TNFα levels were measured in the
supernatant by using sandwich ELISA
kits (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’s in-
structions. For measuring tissue cytokine
levels, liver and pancreas tissues of STZ-
treated mice (see below) were homoge-
nized in cell lysis buffer containing 1%
Triton X-100, and the IL-6 levels were
measured as described above.
STZ-Induced Diabetic Mice
Female Balb/c mice 6 wks of age from
Orient Biology (Seoungnam Kyeonggi-do,
South Korea) were housed under a 12-h
light–dark cycle at 23°C and given re-
stricted access to food and water. Animal
experiments were approved by the Insti-
tutional Animal Care and Use Committee
at Konkuk University. For induction of di-
abetes, the mice (n = 5 in each group)
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were fasted for 3 h before intraperitoneal
injection with a STZ solution (Sigma-
Aldrich; 120 mg/kg body weight) in 
0.05 mol/L sodium citrate buffer (pH 4.5);
these solutions were prepared immedi-
ately before use. After injection, the mice
were fasted for another 3 h and were then
provided ad libitum access to a diet. To
induce sufficient levels of hyperglycemia,
the mice were treated with the same dose
of STZ after 3 d. The mice were then
tested daily for blood glucose levels after
the initial injection. Blood glucose levels
were determined by testing a drop of
blood from an incision in the tip of the tail
with a handheld blood glucose meter (So-
lartek Products, Alameda, CA, USA). For
nonfasting blood glucose readings, a
blood glucose level >250 mg/dL was set
as the lower limit, indicative of the pres-
ence of diabetes (%).
Statistical Analysis
The data were expressed as mean ±
standard error of the mean (SEM). The
statistical significance of differences was
analyzed using the unpaired two-tailed
Student t test. Values of p < 0.05 were
considered statistically significant.
RESULTS
Expression of Recombinant Fc-Human
AAT
Currently, several forms of AAT that
have been purified from human plasma
are available. However, we sought to
produce a standardized recombinant
form of AAT from CHO cells. The intact
human AAT gene, encoding a protein of
418 amino acids, under the control of the
chicken β-actin promoter, was trans-
fected into CHO cells and stable transfec-
tants were isolated. Although we were
able to confirm the transfection of the
human AAT gene by RT-PCR, compared
with a mock transfection of CHO cells,
recombinant AAT protein was not detect-
able in the cell culture supernatant (data
not shown). We further examined the cell
lysate of AAT-transfected CHO cells and
found that most of the recombinant AAT
protein remained inside the cells, despite
the presence of a typical hydrophobic
signal peptide at the N-terminus of AAT.
To circumvent the retention of recombi-
nant AAT protein in CHO cells, we fused
the human AAT gene to a DNA fragment
encoding the Fc domain of human IgG1
and transfected the Fc-fused human AAT
gene into CHO cells for further analysis.
Interestingly, a large amount of recombi-
nant AAT-Fc was released into the cell
culture supernatant, which was con-
firmed by silver staining and Western
blotting analysis (Figure 1). We purified
recombinant AAT-Fc by using protein A
affinity chromatography, and the purified
AAT-Fc was analyzed by SDS-PAGE and
silver staining analysis (Figure 1A). In ad-
dition, we performed Western blotting
analysis of the purified AAT-Fc protein
by using two different antibodies: anti-
human IgG (Figure 1C) and anti-human
AAT (Figure 1D). A schematic illustration
of the recombinant AAT-Fc visualized by
silver staining is depicted in Figure 1B.
Under the nonreduced conditions, recom-
binant AAT-Fc appeared as several large
bands above 170 kDa and as bands at ap-
proximately 160, 85 and 55 kDa; whereas
under the reduced conditions, a major
band was seen at 85 kDa. An anti-human
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Figure 1. Purification of recombinant human AAT-Fc. AAT-Fc was purified by using protein
A affinity chromatography. The eluted fractions were analyzed by silver staining and West-
ern blotting under the reduced (with 2-mercaptoethanol [2-ME]) and nonreduced condi-
tions. (A) The silver staining results indicated that the molecular size of the nonreduced
AAT-Fc protein was approximately 160 kDa (dimer; major band), whereas that of the re-
duced AAT-Fc protein was 85 kDa (monomer). (B) Schematic representation of AAT-Fc in
the dimeric form, connected by two disulfide bonds in the hinge region. Western blotting
with anti-human IgG1 (C) and rabbit anti-human AAT antibodies (D) indicated the pres-
ence of AAT-Fc protein in the eluates. Representative data from one of five independent
experiments are shown.
IgG antibody (Figure 1C) recognized
most of the bands that were detected on
performing silver staining. We also used
a rabbit anti-human AAT polyclonal anti-
body to confirm the presence and purity
of the recombinant AAT-Fc protein, and
the results were similar to those obtained
with anti-IgG1; however, the rabbit anti-
human AAT polyclonal antibody recog-
nized only the 170-kDa band under the
nonreduced conditions or the 85-kDa
band under the reduced conditions (Fig-
ure 1D).
AAT-Fc Suppresses TNFα-Induced IL-6
Production in Human PBMCs
Besides the classic biological activity of
AAT (that is, inhibition of serine pro-
teinase enzyme activity), plasma-derived
human AAT possesses antiinflammatory
activity. Therefore, we examined whether
AAT-Fc possesses a similar biological
property. Human PBMCs were pretreated
with AAT-Fc or plasma-derived AAT for
1 h and then stimulated with TNFα
overnight. The next day, the cell culture
medium was harvested and IL-6 concen-
trations were assessed by using ELISA.
Stimulation with TNFα (10 ng/mL) in-
creased IL-6 production significantly (Fig-
ure 2A). The induction of IL-6 was sup-
pressed by pretreatment with AAT-Fc in a
dose-dependent manner, and a high con-
centration of AAT-Fc (13 nmol/L) com-
pletely abolished IL-6 production. How-
ever, the same concentration of plasma-
derived AAT failed to suppress IL-6
production (Figure 2A). We further inves-
tigated LPS-induced IL-6 production, and
the results showed that both AAT-Fc and
plasma-derived AAT failed to inhibit
LPS-induced IL-6 production in human
PBMCs (Figure 2B).
AAT-Fc Inhibits TNFα Production
Induced by Various Cytokines
Further investigation of the antiinflam-
matory effect of AAT-Fc was performed
with mouse Raw 264.7 cells stimulated
with various cytokines, including LPS.
AAT-Fc reduced human IL-32γ–, human
IL-33– and mouse IL-33–induced TNFα
production in mouse Raw 264.7 cells, but
the same concentration of plasma-derived
AAT failed to suppress TNFα production
(Figure 3). However, AAT-Fc failed to
suppress LPS-induced TNFα production,
consistent with the effect on IL-6 produc-
tion in human PBMCs (Figure 2B).
Human AAT-Fc Decreased Blood
Glucose Levels in the STZ-Induced
Diabetic Mouse Model
Previous studies evaluated the antiin-
flammatory function of plasma-derived
AAT and found that AAT prolonged islet
graft survival and decreased hyperglyce-
mia in the STZ-induced diabetic mouse
model. We evaluated the effects of 
AAT-Fc on hyperglycemia in STZ-
 induced diabetic mice. AAT-Fc (2 mg/kg
body weight) was administered through
intraperitoneal injection on d 0. A low
dose of STZ was injected twice (on d 1
and 3) to induce diabetes, and blood
glucose levels were monitored (Figure 4).
At d 6 (3 d after the second injection),
dramatic enhancement of the blood glu-
cose level was observed (Figure 4). On 
d 13, AAT-Fc–injected mice had lower
glucose levels than the nontreated con-
trol mice, but the difference was not sta-
tistically significant. On d 15 and 17, the
blood glucose level of AAT-Fc–treated
mice was significantly lower than that of
nontreated control mice (Figure 4). To in-
vestigate the mechanism underlying
AAT-Fc–mediated effects on inflamma-
tion in the mouse model of STZ-induced
diabetes, we examined the levels of in-
flammatory cytokines in the pancreas
and liver; the IL-6 level was found to be
lower in AAT-Fc–treated mice than in
control mice not treated with AAT-Fc
(Figure 4B).
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Figure 2. Dose-dependent suppression of TNFα-induced IL-6 production in human PBMCs.
(A) AAT-Fc inhibited TNFα-induced IL-6 production in a dose-dependent manner, and AAT-
Fc used at a concentration of 13 nmol/L abolished IL-6 production completely. However,
the same concentration of plasma-derived AAT has no effect on IL-6 induction. (B) Unlike
the effects of AAT on TNFα-induced IL-6 production, both AAT-Fc and AAT failed to sup-
press LPS-induced IL-6 production. The mean ± SEM values of three independent experi-
ments have been shown. **p < 0.01; ***p < 0.001 (n = 3 per group).
Figure 3. Cytokine-induced TNFα produc-
tion in mouse Raw 264.7 cells is suppressed
by AAT-Fc. Human IL-32γ–, human IL-33–
and mouse IL-33–induced TNFα production
was suppressed by AAT-Fc, but AAT-Fc had
no effect on LPS-induced mouse TNFα. The
plasma-derived AAT had no effect on the
suppression of TNFα. The mean ± SEM val-
ues of two independent experiments have
been shown. *p < 0.05; **p < 0.01 (n = 3 per
group).
Biochemical Analysis of Elastase
Activity in the Presence of AAT-Fc
AAT is a serine proteinase inhibitor
that blocks the enzymatic activity of
neutrophil elastase. We examined
whether AAT-Fc inhibits this elastase.
Plasma- derived AAT and AAT-Fc (two
different concentrations) were preincu-
bated with elastase for 20 min at room
temperature and then added to tubes
containing recombinant IL-32γ, an elas-
tase substrate. After 15 min of incuba-
tion at room temperature, the samples
were subjected to Western blot analysis.
Elastase fragmented the 40-kDa IL-32γ,
resulting in the formation of a cleaved
IL-32γ at 20 kDa (Figure 5); AAT treat-
ment at a 1:5 molar ratio completely
abolished the enzymatic activity of elas-
tase (Figure 5), compared with that of
elastase untreated with AAT (Figure 5).
The same experiment performed with
AAT-Fc at a higher molar ratio (1:25)
failed to block the cleavage of IL-32γ by
elastase (Figure 5).
We further evaluated the effect of 
AAT on elastase activity by using an 
IL-32γ–specific ELISA for measuring the
stability of IL-32γ. In this experiment, 
IL-32γ (100 ng/mL) was mixed with only
elastase or with elastase that had been
preincubated with either plasma-derived
AAT or AAT-Fc for 15 min at room tem-
perature, followed by measurement of 
IL-32γ concentrations by ELISA. Plasma-
derived AAT protected IL-32γ from 
elastase-mediated cleavage (black bar,
Figure 6A), whereas only 15% of the 
IL-32γ remained in the absence of AAT
(open bar, Figure 6A). We examined the
effect of AAT-Fc with the same assay and
found that, unlike plasma- derived AAT,
AAT-Fc failed to protect IL-32γ from elas-
tase-mediated cleavage (Figure 6B).
DISCUSSION
To our knowledge, this study is the
first to report the production of much re-
combinant AAT-Fc and the characteriza-
tion of its biological activity in vitro and
in vivo. We designed a mammalian ex-
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Figure 4. AAT-Fc suppresses hyperglycemia in the STZ-induced mouse model of diabetes.
(A) Six-week-old BALBC/6 mice were administered AAT-Fc (2 mg/kg body weight), and
then a low dose of STZ (120 mg/kg body weight) was injected twice, on d 1 and 3. The
blood glucose level was monitored daily. After the second injection on d 3, the blood glu-
cose level increased significantly. At d 15 and 17, mice that received AAT-Fc had de-
creased blood glucose levels. (B) At d 10 after the STZ injection, the mice were sacrificed,
and the IL-6 level was measured in the liver and pancreas. The mean ± SEM values have
been shown (n = 5 per group). *p < 0.05; **p < 0.01.
Figure 5. Western blot for examining the in-
hibitory effect of AAT-Fc against elastase.
IL-32γ (20 ng) was mixed with elastase 
(20 ng) in the presence or absence of
plasma-derived AAT or AAT-Fc. The
plasma-derived AAT blocked IL-32γ cleav-
age in a 1:5 molar ratio, but AAT-Fc failed
to inhibit IL-32γ cleavage. The molar ratio
of elastase and AAT in each reaction is in-
dicated on the top. The elastase-cleaved
IL-32γ product appeared as a band of ap-
proximately 20 kDa. Representative data
from one of four independent experiments
are shown.
pression vector to express an Fc-fusion
protein containing the constant domain
of human IgG1 (CH2 and CH3), includ-
ing two cysteine residues in the hinge re-
gion, fused to the C-terminus of human
AAT to facilitate the dimerization of the
AAT-Fc molecule (Figure 1). As shown by
silver staining and Western blot analyses,
the recombinant purified AAT-Fc protein
appeared as a dimer under the nonre-
duced conditions, whereas it migrated as
a monomer under the reduced conditions
(Figure 1, indicated by 2-mercaptoethanol
[ME]).
Plasma-derived AAT augmentation
therapy has been approved only for
treatment of AAT deficiency in select
adults with severe pulmonary emphy-
sema. Recently, augmentation therapy
has proven to be highly efficacious in
small cohorts of patients with uncom-
mon AAT deficiency–related diseases
such as fibromyalgia, systemic vasculitis,
relapsing panniculitis and bronchial
asthma (25–27). In addition to these stud-
ies, a series of mouse model studies has
described the efficacy of AAT under
other conditions, including diabetes mel-
litus, organ transplant rejection and
acute myocardial ischemia-reperfusion
injury (1,3,4,6,28,29). These results have
led to an expanding number of medical
applications of AAT, such as allogeneic
hematopoietic cell transplantation in pa-
tients with acute rejection (30,31).
Therefore, it would be useful and
timely to implement new strategies for
producing AAT. In this study, we pro-
duced recombinant AAT-Fc in CHO cells,
tested the antiinflammatory effect of
AAT-Fc on TNFα- or LPS-induced cy-
tokine production in human PBMCs and
compared the functions of plasma-de-
rived AAT and our recombinant AAT-Fc.
The recombinant AAT-Fc sufficiently
suppressed TNFα-induced IL-6 produc-
tion but failed to suppress LPS-induced
IL-6. However, the same concentration of
AAT failed to inhibit the activities of
both TNFα and LPS; similar results were
obtained in mouse Raw 264.7 cells. Previ-
ous studies have used AAT at concentra-
tions that are at least several hundred
times higher than that used in this exper-
iment (4,20,21); this difference likely ac-
counts for the lack of inhibition of TNFα
and other inflammatory cytokines activi-
ties in our assays.
Recent studies on the antiinflammatory
effects of AAT have suggested that these
effects are independent of the inhibitory
activity of serine proteinase (4,19,21) and
that the ZZ allele mutation, which causes
the formation of polymeric AAT (19), af-
fects innate immunity, including inhibi-
tion of the T-cell immunity related to
adaptive immunity (1,4). Nevertheless,
growing evidence proposes that AAT pos-
sesses antiinflammatory functions that are
independent of its inhibitory effects on
serine proteinases. We also examined the
effect of plasma-derived AAT and AAT-Fc
on the enzymatic activity of elastase. In-
terestingly, plasma-derived AAT specifi-
cally blocked IL-32γ cleavage by elastase,
whereas AAT-Fc could not block it. We
cannot exclude AAT-Fc–mediated inhibi-
tion of other serine proteinases, since we
evaluated the enzymatic activity of elas-
tase on a single substrate (IL-32γ).
Numerous studies on plasma-derived
AAT have shown that it protects insulin-
producing β-cells in islets under different
circumstances such as allogeneic islet
transplantation (1,6,8,32,33) and treatment
of NOD mice (2,5,7,28). Moreover, clinical
studies have suggested that circulating
AAT in plasma is associated with type 1
and type 2 diabetes (9,11–13,34–38). These
studies led us to examine whether AAT-Fc
exerts similar effects in the STZ-induced
mouse model of diabetes. During earlier
time points after induction of diabetes,
there was no difference between non-
treated control and AAT-Fc–treated mice.
However, at 15 d after the first injection of
STZ, the AAT-Fc–treated mice had signifi-
cantly improved blood glucose levels
compared with the mice treated with STZ
alone; furthermore, these levels were sus-
tained until d 17. These data suggest that
AAT-Fc protects insulin-producing β-cells
from STZ-induced diabetes. The mecha-
nism underlying AAT-Fc–mediated anti-
inflammatory effects probably involves
the suppression of IL-6 production in the
pancreas, subsequently resulting in re-
duced hyperglycemia in the STZ-induced
mouse model of diabetes.
CONCLUSION
To our knowledge, this study is the
first to report a method for the produc-
tion of much soluble recombinant AAT-Fc
protein. The recombinant AAT-Fc protein
was synthesized in CHO cells as a
chimeric protein fused to the constant re-
gion of IgG1 and was purified by using
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Figure 6. Quantitative analysis of the pro-
teinase inhibitory activity of AAT on elas-
tase, with IL-32γ as the substrate. The IL-32γ
concentrations of reactions containing 
IL-32γ (100 ng/mL) alone or reactions con-
taining IL-32γ with elastase in the presence
or absence of plasma-derived AAT (A) or
AAT-Fc (B) were measured using ELISA, as
described in Materials and Methods. The
molar ratio of elastase and plasma-derived
AAT in the reaction is indicated. In the ab-
sence of plasma-derived AAT, only 15% of
IL-32γ remained at the end of the reaction,
whereas plasma-derived AAT completely
blocked IL-32γ cleavage (A). However, AAT-
Fc failed to block IL-32γ cleavage by elas-
tase (B). Representative data from one of
five independent experiments are shown.
protein A affinity chromatography. The
AAT-Fc antiinflammatory activity was
evaluated by monitoring the suppression
of IL-6 and TNFα by using in vitro assays.
In addition, AAT-Fc protein was found to
prevent hyperglycemia and inflammatory
processes in the STZ- induced mouse
model of diabetes. Further studies on
AAT-Fc in various autoinflammatory dis-
ease models will help identify and de-
velop other clinical applications of 
AAT-Fc, including the potential replace-
ment of plasma-derived AAT in therapy.
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